Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease

Eugene O'Hare, David I.C. Scopes, Eun-Mee Kim, Philip Palmer, David Spanswick, Bridgeen McMahon, Hozefa Amijee, Edmund Nerou, J. Mark Treherne, Ross Jeggo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer's disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhibitor, SEN1576. Binding of SEN1576 to monomeric Aβ1–42 was measured using surface plasmon resonance. Thioflavin-T and MTT assays determined the ability of SEN1576 to block Aβ1–42-induced aggregation and reduction in cell viability, respectively. In vivo long-term potentiation (LTP) determined effects on synaptic toxicity induced by intracerebroventricular (i.c.v.) injection of cell-derived Aβ oligomers. An operant behavioural schedule measured effects of oral administration following i.c.v. injection of Aβ oligomers in normal rats. SEN1576 bound to monomeric Aβ1–42, protected neuronal cells exposed to Aβ1–42, reduced deficits in in vivo LTP and behaviour. SEN1576 exhibits the necessary features of a drug candidate for further development as a disease modifying treatment for the early stages of AD-like dementia.
LanguageEnglish
Pages117-126
Number of pages9
JournalThe International Journal of Neuropsychopharmacology
Volume17
Issue number01
Early online date8 Oct 2013
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Alzheimer Disease
Amyloid
Long-Term Potentiation
Dementia
Therapeutics
Injections
Aptitude
Surface Plasmon Resonance
Oral Administration
Cell Survival
Appointments and Schedules
SEN1576
Pharmaceutical Preparations

Keywords

  • Alternating-lever cyclic-ratio schedule
  • amyloid-β
  • Alzheimer's disease
  • long-term potentiation
  • oligomeric Aβ

Cite this

O'Hare, Eugene ; Scopes, David I.C. ; Kim, Eun-Mee ; Palmer, Philip ; Spanswick, David ; McMahon, Bridgeen ; Amijee, Hozefa ; Nerou, Edmund ; Treherne, J. Mark ; Jeggo, Ross. / Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. In: The International Journal of Neuropsychopharmacology. 2014 ; Vol. 17, No. 01. pp. 117-126.
@article{87d1ed5f5967425fb52f3321dcf3a13f,
title = "Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease",
abstract = "Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer's disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhibitor, SEN1576. Binding of SEN1576 to monomeric Aβ1–42 was measured using surface plasmon resonance. Thioflavin-T and MTT assays determined the ability of SEN1576 to block Aβ1–42-induced aggregation and reduction in cell viability, respectively. In vivo long-term potentiation (LTP) determined effects on synaptic toxicity induced by intracerebroventricular (i.c.v.) injection of cell-derived Aβ oligomers. An operant behavioural schedule measured effects of oral administration following i.c.v. injection of Aβ oligomers in normal rats. SEN1576 bound to monomeric Aβ1–42, protected neuronal cells exposed to Aβ1–42, reduced deficits in in vivo LTP and behaviour. SEN1576 exhibits the necessary features of a drug candidate for further development as a disease modifying treatment for the early stages of AD-like dementia.",
keywords = "Alternating-lever cyclic-ratio schedule, amyloid-β, Alzheimer's disease, long-term potentiation, oligomeric Aβ",
author = "Eugene O'Hare and Scopes, {David I.C.} and Eun-Mee Kim and Philip Palmer and David Spanswick and Bridgeen McMahon and Hozefa Amijee and Edmund Nerou and Treherne, {J. Mark} and Ross Jeggo",
year = "2014",
month = "1",
day = "1",
doi = "10.1017/S1461145713000886",
language = "English",
volume = "17",
pages = "117--126",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
number = "01",

}

O'Hare, E, Scopes, DIC, Kim, E-M, Palmer, P, Spanswick, D, McMahon, B, Amijee, H, Nerou, E, Treherne, JM & Jeggo, R 2014, 'Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease', The International Journal of Neuropsychopharmacology, vol. 17, no. 01, pp. 117-126. https://doi.org/10.1017/S1461145713000886

Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. / O'Hare, Eugene; Scopes, David I.C.; Kim, Eun-Mee; Palmer, Philip; Spanswick, David; McMahon, Bridgeen; Amijee, Hozefa; Nerou, Edmund; Treherne, J. Mark; Jeggo, Ross.

In: The International Journal of Neuropsychopharmacology, Vol. 17, No. 01, 01.01.2014, p. 117-126.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease

AU - O'Hare, Eugene

AU - Scopes, David I.C.

AU - Kim, Eun-Mee

AU - Palmer, Philip

AU - Spanswick, David

AU - McMahon, Bridgeen

AU - Amijee, Hozefa

AU - Nerou, Edmund

AU - Treherne, J. Mark

AU - Jeggo, Ross

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer's disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhibitor, SEN1576. Binding of SEN1576 to monomeric Aβ1–42 was measured using surface plasmon resonance. Thioflavin-T and MTT assays determined the ability of SEN1576 to block Aβ1–42-induced aggregation and reduction in cell viability, respectively. In vivo long-term potentiation (LTP) determined effects on synaptic toxicity induced by intracerebroventricular (i.c.v.) injection of cell-derived Aβ oligomers. An operant behavioural schedule measured effects of oral administration following i.c.v. injection of Aβ oligomers in normal rats. SEN1576 bound to monomeric Aβ1–42, protected neuronal cells exposed to Aβ1–42, reduced deficits in in vivo LTP and behaviour. SEN1576 exhibits the necessary features of a drug candidate for further development as a disease modifying treatment for the early stages of AD-like dementia.

AB - Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer's disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhibitor, SEN1576. Binding of SEN1576 to monomeric Aβ1–42 was measured using surface plasmon resonance. Thioflavin-T and MTT assays determined the ability of SEN1576 to block Aβ1–42-induced aggregation and reduction in cell viability, respectively. In vivo long-term potentiation (LTP) determined effects on synaptic toxicity induced by intracerebroventricular (i.c.v.) injection of cell-derived Aβ oligomers. An operant behavioural schedule measured effects of oral administration following i.c.v. injection of Aβ oligomers in normal rats. SEN1576 bound to monomeric Aβ1–42, protected neuronal cells exposed to Aβ1–42, reduced deficits in in vivo LTP and behaviour. SEN1576 exhibits the necessary features of a drug candidate for further development as a disease modifying treatment for the early stages of AD-like dementia.

KW - Alternating-lever cyclic-ratio schedule

KW - amyloid-β

KW - Alzheimer's disease

KW - long-term potentiation

KW - oligomeric Aβ

UR - https://pure.ulster.ac.uk/en/searchAll/index/?search=11486806&pageSize=25&showAdvanced=false&allConcepts=true&inferConcepts=true&searchBy=PartOfNameOrTitle

U2 - 10.1017/S1461145713000886

DO - 10.1017/S1461145713000886

M3 - Article

VL - 17

SP - 117

EP - 126

JO - International Journal of Neuropsychopharmacology

T2 - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 01

ER -